Johnson & Johnson subsidiary Janssen Pharmaceutica NV has confirmed to deliver 220 million doses of its COVID-19 vaccine to the African Vaccine Acquisition Trust (AVAT).
https://european-biotechnology.com/wp-content/uploads/2024/04/JNJ.jpg8531280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-03-30 08:15:382021-03-30 08:15:38Janssen to pledge COVID-19 vaccine to African Union
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2021-03-24 11:12:002021-03-24 11:12:00Abivax with new CMO
https://european-biotechnology.com/wp-content/uploads/2024/04/T_cell_lymphoma.jpg8001200Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-03-24 09:39:242021-03-24 09:39:24Step Pharma SAS raises €35m in Series B
The future of AAV vector-based therapies holds great promise if manufacturers can cope with the demand. While in-house manufacturing may be an option for some companies, partnering with a CDMO can be the best choice for others. Teaming up with a One-Stop-Shop CDMO can make it easier to achieve the project goals. There are many reasons for this.
https://european-biotechnology.com/wp-content/uploads/2024/04/EBM.com_Spring_2021_Biovian_kl.jpg7311300Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-03-23 14:50:002024-04-02 16:20:10AAV vectors from a CDMO that cares about SMEs
The threat caused by the SARS-CoV-2 virus is a global one. Therefore, we have to address the coronavirus pandemic globally, but at least on a European scale. To achieve this, we need not only a vaccination strategy but also a therapy strategy.
Exosome Diagnostics develops biofluid-based molecular diagnostic tests for use in personalized medicine and collaborates with pharmaceutical companies to develop companion diagnostics (CDx).
The German Patent System has been a very patentee-friendly system, in particular for smaller patentees. Enforcement of patents has been relatively easy, affordable and fast.
https://european-biotechnology.com/wp-content/uploads/2024/04/2017spring-ute-kilger.jpg5621000Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-03-23 12:25:002024-04-02 16:20:11Modernisation of patent law – boon or bane for patentees?
https://european-biotechnology.com/wp-content/uploads/2024/04/Impfung.jpg5641156Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-03-23 07:19:002021-03-23 07:19:00AZD1222 claims 79% effecacy in pivotal US study
Janssen to pledge COVID-19 vaccine to African Union
Latest NewsJohnson & Johnson subsidiary Janssen Pharmaceutica NV has confirmed to deliver 220 million doses of its COVID-19 vaccine to the African Vaccine Acquisition Trust (AVAT).
Bispecific IgG switch off SARS-CoV-2 escape variants
Latest NewsA bispecific antibody designed by a Swiss-Czech research team suppressed viral escape of SARS-CoV-2 variants in animals.
Abivax with new CMO
AppointmentsAt the beginning of March, Dr Sophie Biguenet has been the new Chief Medical Officer of Paris-based Abivax SA.
European Biotechnology Guide 2021
Sponsored PublicationsThe 11th edition of the European Biotechnology Science & Industry Guide once more offers an interesting cross-section of the European biotech scene.
Step Pharma SAS raises €35m in Series B
Latest NewsKurma Partners-founded Step Pharma has baged €35m in a Series B financing to advance its blood cancer lead STP938.
AAV vectors from a CDMO that cares about SMEs
BackgroundThe future of AAV vector-based therapies holds great promise if manufacturers can cope with the demand. While in-house manufacturing may be an option for some companies, partnering with a CDMO can be the best choice for others. Teaming up with a One-Stop-Shop CDMO can make it easier to achieve the project goals. There are many reasons for this.
Europe needs a strategy
Latest NewsThe threat caused by the SARS-CoV-2 virus is a global one. Therefore, we have to address the coronavirus pandemic globally, but at least on a European scale. To achieve this, we need not only a vaccination strategy but also a therapy strategy.
IZB Start-up: Exosome Diagnostics
Sponsored PublicationsExosome Diagnostics develops biofluid-based molecular diagnostic tests for use in personalized medicine and collaborates with pharmaceutical companies to develop companion diagnostics (CDx).
Modernisation of patent law – boon or bane for patentees?
BackgroundThe German Patent System has been a very patentee-friendly system, in particular for smaller patentees. Enforcement of patents has been relatively easy, affordable and fast.
AZD1222 claims 79% effecacy in pivotal US study
Latest NewsFollowing assemingly good results in a Phase III study AstraZeneca goes for Emergency Use Approval in the US.